IMUGENE LIMITED — Director's Dealing 2018

Oct 21, 2018

ASX RELEASE

22 October 2018

==> picture [168 x 74] intentionally omitted <==

Dr Axel Hoos (Non-Executive Director) exercises 10 million options

On 19 October 2018, Dr Hoos, a Non-Executive Director, elected to exercise 10 million unlisted options at $0.015 per share. As a result, Dr Hoos’ shareholding in the Company increased from 7.5 million shares to 10 million shares.

Please find the attached Appendix 3Y which captures the changes in his holding.

Further details are available on the accompanying Appendix 3Y.

-END-

IMUGENE LIMITED ACN 009 179 551 Phone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

	Imugene Limited (ASX:IMU)
Name of Entity:
	009 179 551
ACN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Axel Hoos
Date of Last Notice:	11 December 2017

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Direct or Indirect Interest		Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to therelevant interest.
Date of change		19 October 2018
No. of securities held prior to change				Options25,000,000-25,000,000
			Shares	Options
		Direct	7,500,000	25,000,000
		Indirect	-	-
		Total	7,500,000	25,000,000
Class		Ordinary Shares and Options
Number acquired				Options---
			Shares	Options
		Direct	10,000,000	-
		Indirect	-	-
		Total	10,000,000	-
Number disposed				Options10,000,000-10,000,000
			Shares	Options
		Direct	7,500,000	10,000,000
		Indirect	-	-
		Total	7,500,000	10,000,000

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/ConsiderationNote:If consideration is non-cash, provide details and estimatedvaluation		Non-cash, see ‘nature of change’ below.	Non-cash, see ‘nature of change’ below.	Non-cash, see ‘nature of change’ below.
No. of securities held after change				Options15,000,000-15,000,000
			Shares	Options
		Direct	10,000,000	15,000,000
		Indirect	-	-
		**Total **	10,000,000	15,000,000
Nature of changeExample:on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestment plan, participation in buy-back		On-market trade for disposal of 7,500,000shares @ $0.02 each ($150,000 total) to fundthe exercise of 10,000,000 options into10,000,000 shares @ $0.015 each ($150,000total).

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which	N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change	N/A

Part 3 – Closed period

Were the interests in	the securities or	No
contractsdetailed	abovetraded
during a +closed period where prior
written clearance was required?
If so, was prior written clearance		N/A
provided to allow the	trade to proceed
during this period?
Ifprior written	clearance was	N/A
provided, on what	date was this
provided?

==> picture [39 x 23] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

22 October 2018

Appendix 3Y Page 2

01/01/2011